Literature DB >> 9132081

New developments in the treatment of hypoplastic left heart syndrome.

D M Cohen1, H D Allen.   

Abstract

Progress has been made in the treatment of children born with hypoplastic left heart syndrome. From a mortality of more than 95% at 1 month of age in an era prior to surgical intervention, an actuarial survival of 58% at 5 years of age for staged surgical palliation is now being achieved. The short-term results with cardiac transplantation also appear to be excellent. Efforts are being directed at identifying potential risk factors, and fetal ultrasonography is capable of monitoring the progression of this malformation in utero. Refinements in surgical technique and postoperative care have been achieved, reducing the overall risk of the Norwood operation and sudden hemodynamic instability in the intensive care unit. Practice patterns and perceptions of outcome vary widely. Presently there is no unanimity of opinion that surgical therapy should be offered to all patients, and comfort care continues to be a family option.

Entities:  

Mesh:

Year:  1997        PMID: 9132081     DOI: 10.1097/00001573-199701000-00008

Source DB:  PubMed          Journal:  Curr Opin Cardiol        ISSN: 0268-4705            Impact factor:   2.161


  3 in total

1.  Changes in the aortic and pulmonary diameters in a fetus with hypoplastic left heart syndrome.

Authors:  Katsuhiko Tada; Satoshi Yamada; Kazumasa Kumazawa; Masayo Takata; Takakimi Nakata; Hisashi Masuyama; Mikiya Nakatsuka; Takafumi Kudo; Shin-Ichi Otsuki
Journal:  J Med Ultrason (2001)       Date:  2003-06       Impact factor: 1.314

2.  Hypoplastic left heart syndrome: Prognosis and management options.

Authors:  D S Fruitman
Journal:  Paediatr Child Health       Date:  2000-05       Impact factor: 2.253

3.  Choices doctors would make if their infant had hypoplastic left heart syndrome: comparison of survey data from 1999 and 2007.

Authors:  Alexander A Kon; Milan Prsa; Charles V Rohlicek
Journal:  Pediatr Cardiol       Date:  2012-08-15       Impact factor: 1.655

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.